Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 6.2% - What's Next?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) traded down 6.2% during trading on Monday . The stock traded as low as $4.98 and last traded at $4.95. 4,679,937 shares traded hands during trading, a decline of 71% from the average session volume of 15,996,274 shares. The stock had previously closed at $5.27.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 target price for the company. Needham & Company LLC reaffirmed a "buy" rating and issued a $8.00 price objective on shares of Recursion Pharmaceuticals in a report on Tuesday. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $7.00.

Recursion Pharmaceuticals Trading Up 2.3%

The company has a fifty day simple moving average of $4.82 and a 200-day simple moving average of $6.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.11 and a quick ratio of 4.11.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.39) earnings per share. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. ARK Investment Management LLC raised its position in shares of Recursion Pharmaceuticals by 7.6% in the first quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after purchasing an additional 2,469,104 shares during the period. Vanguard Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 40.1% in the fourth quarter. Vanguard Group Inc. now owns 34,009,994 shares of the company's stock worth $229,908,000 after acquiring an additional 9,737,196 shares during the last quarter. Softbank Group CORP. acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter worth $99,152,000. Kinnevik AB publ boosted its stake in Recursion Pharmaceuticals by 12.8% during the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after buying an additional 1,528,503 shares in the last quarter. Finally, Novo Holdings A S acquired a new stake in Recursion Pharmaceuticals during the fourth quarter worth $68,375,000. Institutional investors own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.